Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670720 | 0.94 | ALDH1A1 (0.54) | ALDH1A1HPGDSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL17234481 | 0.88 | ALDH1A1 (0.60) | ALDH1A1HPGDLMNAKMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL6496568 | 0.85 | ALDH1A1 (0.44) | ALDH1A1HPGDSMN1; SMN2KMT2ACDC25A | |
| SCHEMBL13007600 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL5849540 | 0.80 | LMNA (0.57) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL3131322 | 0.79 | KDM4E (0.53) | LMNAKMT2AKDM4EGRIN2DGRIN3B | |
| SCHEMBL4394126 | 0.79 | ITGB3 (0.64) | ALDH1A1SMN1; SMN2GAAITGB3ITGAV | |
| SCHEMBL18794901 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDLMNASMN1; SMN2KMT2A | |
| SCHEMBL5509361 | 0.78 | ALDH1A1 (0.52) | ALDH1A1HPGDLMNAKMT2AGAA | |
| SCHEMBL10767538 | 0.77 | MAPK1 (0.49) | ALDH1A1LMNASMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239211-A1 | Method For Enrichment Involving Elimination By Mismatch Hybridisation | NUEVOLUTION A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090239211-A1 | Method For Enrichment Involving Elimination By Mismatch Hybridisation | NUEVOLUTION A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| CN-1146541-C | Beta-alanine derivatives | Ĭ��ר���ɷ�����˾ | 2004-04-21 | — | — | CN | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6576637-B1 | Such as 3-(4-methyl-3-nitrophenyl)-3-(2-(4-(pyridin-2-yl-amino)butyryl amino)acetylamino)propionic acid; thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, | MERCK PATENT GMBH (DE) | 2003-06-10 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| CN-1340046-A | Beta-alanine derivatives | MERCK PATENT GMBH (DE) | 2002-03-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | ALDH1A1 3346/4885HPGD 119/4885LMNA 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.